Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
150.57 -6.02 -3.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Founded
1992
CEO
Dr. Kyle W. Gano, PhD
Employees
2,000
Headquarters
San Diego, California, United States of America
Fiscal year end
12-31
Website
neurocrine.com

Company profile

Exchange
US
Symbol
NBIX
Market-cap rank
#1162
Listing date
1970-01-01
Market cap
15.24B
Float cap
15.04B
Shares out
101.22M
Float shares
99.91M

Sectors & themes

Drug Manufacturers - Specialty & Generic Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Neurocrine Biosciences discussion 0 comments

Add a comment